NORTHWEST BIO SHARED RESOURCE (NWBioSR) Northwest Bio Shared Resource (NWBioSR) provides patient consenting, human research biospecimen procurement, and annotation services. Patients are consented for (1) research use of biospecimens and electronic medical records-derived data and (2) enrollment in a registry of patients who consent to future contact for potential enrollment in clinical studies. All biospecimen and data handling is done under Institutional Review Board (IRB)-approved mechanisms. NWBioSR is organized under a Governance Committee with Consortium-wide representation and support. State-of-the-art information systems support operations, allowing broad Consortium access to: ? Registration of studies, associated IRB, and consent information ? Prospective identification of clinical samples, from which research biospecimens likely may be obtained, based on characteristics determined electronically prior to actual arrival of the clinical specimen in the hospital laboratory: 1. at the patient level, such as demographic information 2. at the visit level, such as tumor type and stage information 3. at the biospecimen level, such as aliquot stabilization time ? Procurement of research-only biospecimens, including blood draws obtained specifically for research and research-only biopsies ? Retrospective identification of clinical samples that pre-exist in the hospital laboratories and which may be used/subdivided for research (e.g., archival pathology blocks and slides as well as remnant blood ?leftover? in the laboratory medicine department from earlier clinical draws); ? Detailed annotation information including extensive extraction of medical records data as needed ? Generation of tissue microarrays as well as digital pathology image annotation and analysis of whole slide images ? Dissemination of biospecimen and annotation information through informatics efforts NWBioSR is a heavily-utilized facility, supporting a large number of clinical trials, translational research studies, Consortium biorepository collections, and external projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853653
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Molina, Yamile; Briant, Katherine J; Sanchez, Janeth I et al. (2018) Knowledge and social engagement change in intention to be screened for colorectal cancer. Ethn Health 23:461-479
Winters, Brian R; Vakar-Lopez, Funda; Brown, Lisha et al. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 36:342.e7-342.e14
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655

Showing the most recent 10 out of 1267 publications